PDF(Pubmed)
Abstract：
UNASSIGNED: Porto-sinusoidal vascular disorder (PSVD) encompasses a group of liver diseases with vascular abnormalities that can cause portal hypertension in the absence of cirrhosis. The new diagnostic criteria allow for coexistence with other liver diseases, however its relationship with chronic hepatitis B (CHB) remains unclear. This study aimed to assess HBV prevalence in a PSVD cohort and evaluate its clinical impact.
UNASSIGNED: This retrospective study was conducted on patients with PSVD at Hospital Clínic Barcelona. HBV serology was evaluated, and patients were categorized into HBV chronic infection, past infection, or no HBV exposure. Clinical characteristics and outcomes were compared.
UNASSIGNED: We included 155 patients with PSVD. Prevalence of CHB and past HBV infection in patients with PSVD was higher than in the general population (5.8% vs. 0.5%, p <0.0001 and 20% vs. 9.1%, p <0.0001, respectively). Patients with CHB had a significant delay in PSVD diagnosis compared to those without CHB (11 [5-25] vs. 1 [0-3] years, p = 0.002) and had a more advanced disease (MELD score 12 [9-17] vs. 9 [7-11], p = 0.012) at the time of PSVD diagnosis. The clinical evolution of PSVD in patients with CHB was marked by a significantly higher transplantation rate at the last follow-up (33% vs. 4.1%, p = 0.001).
UNASSIGNED: Recognizing the coexistence of PSVD and CHB is important for timely diagnosis and optimal management, highlighting the potential benefits of specialized care for potentially improved outcomes.
UNASSIGNED: The new diagnostic criteria for porto-sinusoidal vascular disorder (PSVD) allow for coexistence with other liver diseases. The results of the present study highlight, for the first time, a non-negligible prevalence of chronic hepatitis B in the PSVD population that was previously unknown. Coexistence may challenge and delay the PSVD diagnosis and is associated with a more unfavorable clinical course. Our findings will increase awareness of this coexistence and improve PSVD diagnosis and management. Furthermore, the data will encourage new studies to determine the prevalence and clinical behavior of other chronic liver diseases that coexist with PSVD.
UNASSIGNED: This retrospective study was conducted on patients with PSVD at Hospital Clínic Barcelona. HBV serology was evaluated, and patients were categorized into HBV chronic infection, past infection, or no HBV exposure. Clinical characteristics and outcomes were compared.
UNASSIGNED: We included 155 patients with PSVD. Prevalence of CHB and past HBV infection in patients with PSVD was higher than in the general population (5.8% vs. 0.5%, p <0.0001 and 20% vs. 9.1%, p <0.0001, respectively). Patients with CHB had a significant delay in PSVD diagnosis compared to those without CHB (11 [5-25] vs. 1 [0-3] years, p = 0.002) and had a more advanced disease (MELD score 12 [9-17] vs. 9 [7-11], p = 0.012) at the time of PSVD diagnosis. The clinical evolution of PSVD in patients with CHB was marked by a significantly higher transplantation rate at the last follow-up (33% vs. 4.1%, p = 0.001).
UNASSIGNED: Recognizing the coexistence of PSVD and CHB is important for timely diagnosis and optimal management, highlighting the potential benefits of specialized care for potentially improved outcomes.
UNASSIGNED: The new diagnostic criteria for porto-sinusoidal vascular disorder (PSVD) allow for coexistence with other liver diseases. The results of the present study highlight, for the first time, a non-negligible prevalence of chronic hepatitis B in the PSVD population that was previously unknown. Coexistence may challenge and delay the PSVD diagnosis and is associated with a more unfavorable clinical course. Our findings will increase awareness of this coexistence and improve PSVD diagnosis and management. Furthermore, the data will encourage new studies to determine the prevalence and clinical behavior of other chronic liver diseases that coexist with PSVD.
摘要：
■窦口血管疾病（PSVD）包括一组具有血管异常的肝脏疾病，在没有肝硬化的情况下可导致门静脉高压。新的诊断标准允许与其他肝脏疾病共存，然而，其与慢性乙型肝炎（CHB）的关系仍不清楚。本研究旨在评估PSVD队列中的HBV患病率并评估其临床影响。
这项回顾性研究是对巴塞罗那Clínic医院的PSVD患者进行的。HBV血清学评估，和患者被归类为HBV慢性感染，过去的感染，或没有HBV暴露。比较临床特征和结果。
■我们纳入了155例PSVD患者。PSVD患者的CHB和过去HBV感染的患病率高于一般人群（5.8％vs.0.5%,p<0.0001和20%vs.9.1%，p分别<0.0001)。与没有CHB的患者相比，CHB的PSVD诊断显着延迟（11[5-25]vs.1[0-3]年,p=0.002），并且患有更晚期的疾病（MELD评分12[9-17]与9[7-11],p=0.012）在PSVD诊断时。CHB患者PSVD的临床演变在最后一次随访时显著提高了移植率（33％vs.4.1%,p=0.001)。
■认识到PSVD和CHB的共存对于及时诊断和优化管理很重要，强调专业护理对潜在改善结局的潜在好处。
■门窦血管疾病（PSVD）的新诊断标准允许与其他肝脏疾病共存。本研究的结果强调，第一次,以前未知的PSVD人群中慢性乙型肝炎的不可忽视的患病率。共存可能会挑战并延迟PSVD的诊断，并且与更不利的临床过程有关。我们的发现将提高对这种共存的认识，并改善PSVD的诊断和管理。此外，这些数据将鼓励新的研究来确定与PSVD共存的其他慢性肝病的患病率和临床行为.
这项回顾性研究是对巴塞罗那Clínic医院的PSVD患者进行的。HBV血清学评估，和患者被归类为HBV慢性感染，过去的感染，或没有HBV暴露。比较临床特征和结果。
■我们纳入了155例PSVD患者。PSVD患者的CHB和过去HBV感染的患病率高于一般人群（5.8％vs.0.5%,p<0.0001和20%vs.9.1%，p分别<0.0001)。与没有CHB的患者相比，CHB的PSVD诊断显着延迟（11[5-25]vs.1[0-3]年,p=0.002），并且患有更晚期的疾病（MELD评分12[9-17]与9[7-11],p=0.012）在PSVD诊断时。CHB患者PSVD的临床演变在最后一次随访时显著提高了移植率（33％vs.4.1%,p=0.001)。
■认识到PSVD和CHB的共存对于及时诊断和优化管理很重要，强调专业护理对潜在改善结局的潜在好处。
■门窦血管疾病（PSVD）的新诊断标准允许与其他肝脏疾病共存。本研究的结果强调，第一次,以前未知的PSVD人群中慢性乙型肝炎的不可忽视的患病率。共存可能会挑战并延迟PSVD的诊断，并且与更不利的临床过程有关。我们的发现将提高对这种共存的认识，并改善PSVD的诊断和管理。此外，这些数据将鼓励新的研究来确定与PSVD共存的其他慢性肝病的患病率和临床行为.
